The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Study Type
OBSERVATIONAL
Enrollment
10,000
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
The Second Affiliated Hospital of Shantou University
Shantou, Guangdong, China
NOT_YET_RECRUITINGXiangyun County People's Hospital
Xiangyun, Yunnan, China
NOT_YET_RECRUITINGShaoxing Central Hospital
Shaoxing, Zhejiang, China
RECRUITINGPrimary Outcome
Tetanus protection rate within 90 days post-administration of Siltartoxatug Injection (calculated as 1- tetanus incidence rate)
Time frame: within 90 days
Secondary Outcome
Classification of wound characteristics in patients receiving Siltartoxatug Injection
Time frame: within 90 days
Secondary Outcome
Incidence of adverse reactions and serious adverse events within 90 days post-administration of Siltartoxatug Injection
Time frame: within 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Zhoushan Putuo District People's Hospital
Zhoushan, Zhejiang, China
NOT_YET_RECRUITING